Tag Archives: Shows

Fate Therapeutics’ FATE-NK100 shows encouraging action in early-stage ovarian cancer study; shares ahead 5% premarket – Fate Therapeutics, Inc. (NASDAQ:FATE)

Fate Therapeutics (NASDAQ:FATE) is up 5% premarket on light volume on the heels of its announcement of positive preliminary results from a Phase 1 clinical trial evaluating lead immuno-oncology candidate FATE-NK100 in… Read more »